Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer

  • Etude concernée: IFCT-2203
  • Auteurs / Authors: Moro-Sibilot D, Falchero L, Ardin C, Zouak A, Molinier O, Romand P, Leleu O, Amrane K, Berndt C, Langlais A, Morin F, Westeel V
  • Journal / Conference: Respiratory Medicine and Research
  • Année / Year: 2024
  • PMID: 38843598
  • Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/38843598/